Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
Crossref DOI link: https://doi.org/10.1038/srep31391
Published Online: 2016-08-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Perera, G.
Ranola, M.
Rowe, D. B.
Halliday, G. M.
Dzamko, N.
Text and Data Mining valid from 2016-08-09
Version of Record valid from 2016-08-09
Article History
Received: 5 April 2016
Accepted: 19 July 2016
First Online: 9 August 2016
Competing interests
: The authors declare no competing financial interests.